Covid-19

QIAGEN is a leading global provider of molecular Sample to Insight solutions. The company recently launched a syndromic test cartridge kit for the QIAstat-Dx Analyser System that can identify the SARS-CoV-2 coronavirus within an hour. Designed for use in hospitals, clinics and laboratories, the company’s new QIAstat-Dx syndromic testing platform comes in the form of a compact, modular, table-top device into which multi-chamber cartridges containing test samples are inserted for analysis.

For this reason, it implemented all the indications provided for by the Shared Protocol on March 14, 2020 between the Government, Trade Unions and Trade Associations. In order to allow its employees and suppliers to access workplaces in compliance with the precautions that the current serious situation requires to adopt.

The situation with the Coronavirus/COVID-19 is, as I’m sure you’re aware, constantly evolving. Our senior management team are meeting regularly to review the guidance we receive and the advice we give. We have also updated our procedures to ensure we are able to honour our commitments to our team and our customers. Our intention at this time is to maintain an uninterrupted supply chain, this will include functioning production, order processing and technical departments, along with a customer service support team.

Production is maintained in all of our 9 factories worldwide. In the KURZ plants and in our 25 sales branches all over the world, we can react quickly to regional fluctuations. The security and flexibility of raw material supply are also guaranteed thanks to our well-organized supplier network. We therefore currently see no restriction in our customers' delivery. At all of our locations, we have strengthened existing hygiene measures and regulations and made additional protective products such as disinfectants available. Our employees are instructed to comply with international standards.